focus -WSS

focus

author：fashion 2025-10-01 21:09:48 - browse：434

A liver with a smooth and healthy left half and a bumpy, browning right half — chronic disease coverage from STAT — Adobe

Akero Therapeutics said Monday that extending treatment with its experimental drug for the liver disease known as MASH from six months to two years resulted in better outcomes for patients — most notably reductions in liver scarring at a rate three times higher than placebo without worsening other symptoms.

The mid-stage study of the Akero drug called efruxifermin achieved its main goal in September 2022. With longer treatment, more patients with MASH responded to the drug, while those who initially benefited showed durable improvements.

“We’re really pleased with the data. It’s exactly what we were hoping to see,” said Kitty Yale, Akero’s chief development officer, in an interview with STAT. “It’s not just the high response rates, but the fact that responses are sustained and broadened as well.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： CDC advisers recommend seasonal use of Pfizer RSV shot

focus

WSS

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Lasker Awards 2023: Winners in biomedical research

FDA panel to weigh approval of NurOwn, controversial ALS drug

After affirmative action ruling, medical educators look to 'holistic review'

Hepatitis C has a cure — but many Americans still lack access to it

Guidelines to prevent youth baseball injuries need more muscle

focus

focus

explore

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Medical student insurance fails on mental health care coverage

Medical leaders decry Supreme Court decision on affirmative action

Experts study whether long Covid risk adds up with each reinfection

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Walensky prepares to leave CDC — and Congress — behind

BioMarin wins approval for gene therapy to treat hemophilia A

Readout LOUD podcast: possible new ALS drug, artificial wombs

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Emergency workers more likely to restrain Black patients: study

entertainment

In Memoriam: Notable people who died in 2023

United colonoscopy coverage change 'may cost lives,' doctors say

How to save PrEP access — and even expand it

Readout LOUD podcast: possible new ALS drug, artificial wombs

Intarcia’s device

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

focus

focus

explore

knowledge